Korsana Biosciences
Waltham, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The co
Key facts
- Headquarters
- Waltham, Massachusetts, United States
- Employees
- 37
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (KRSA)
- Website
- korsana.com
- Company page
Recent activity at Korsana Biosciences
- : Korsana Biosciences completes a private placement closing, raising $380 million led by Fairmount and Venrock Healthcare Capital Partners to fund operations into 2029.
- : Korsana Biosciences Appoints Matthew Leoni as Chief Medical Officer and Gan Wei as Chief Technical Officer
- : Cyclerion to merge with Korsana Biosciences
- : Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer
- : Korsana Biosciences has secured $175 million in Series A funding to advance its innovative therapeutics for neurodegenerative diseases, co-led by Wellington Management and TCGX.
- : Cyclerion Therapeutics Enters Collaboration Agreement with Medsteer
- : Cyclerion Announces Strategic Agreement with Medsteer for CYC-126 TRD Program.
- : Cyclerion Therapeutics Enters Licensing Agreement with MIT to Advance Treatment-Resistant Depression Therapies
- : Cyclerion Therapeutics
- : Cyclerion Therapeutics, Inc.
Korsana Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $380.0M |
| Feb 2026 | Series A | $175.0M |
| May 2023 | Venture | $5.0M |
| Jun 2021 | Venture | $18.0M |
| Aug 2020 | Venture | $24.3M |
Leadership
- Jason Keller, Senior Director, New Product Planning
- Peter Hecht, Executive Officer, Director
- Kevin Churchwell, Director
- George Conrades, Director
- Errol Souza, Director
- Marsha Fanucci, Director
- Ole Isacson, Director
- Stephanie Lovell, Director
- Terrance McGuire, Director
- Michael Mendelsohn, Director
Verified email and direct lines for Korsana Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Korsana Biosciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Korsana Biosciences in the news
- Korsana Biosciences Strengthens Leadership with Executive and Board Appointments to Support Next Phase of Growth - Business Wire (Aug 03, 2026)
- Korsana Biosciences to Participate in Upcoming Investor Conferences - WBOC TV (Nov 02, 2026)
- Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire (Apr 01, 2026)
- Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody - Fierce Biotech (Feb 18, 2026)
- Korsana Biosciences Completes Cyclerion Merger And $380 Million Private Placement - Pulse 2.0 (Sep 10, 2026)
- Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases - Business Wire (Feb 18, 2026)
- Korsana Biosciences, Inc. (KRSA) Company Information - Simply Wall St (Sep 11, 2026)
Companies similar to Korsana Biosciences
- Q32 Bio · Biotechnology, Healthcare, Health Care, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Therapeutics
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- BioCardia · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About Korsana Biosciences: questions and answers
What does Korsana Biosciences do?
Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The co
Where is Korsana Biosciences headquartered?
Korsana Biosciences is headquartered in Waltham, Massachusetts, United States.
How many employees does Korsana Biosciences have?
Korsana Biosciences has about 37 employees.
Has Korsana Biosciences raised funding?
Yes. Fundz has recorded 5 funding events for Korsana Biosciences. The most recent, Post-IPO Equity of $380.0M, was in Sep 2026.
What is the latest news on Korsana Biosciences?
On Sep 08, 2026, Korsana Biosciences completes a private placement closing, raising $380 million led by Fairmount and Venrock Healthcare Capital Partners to fund operations into 2029.
Is Korsana Biosciences a public company?
Yes. Korsana Biosciences is publicly traded under the ticker KRSA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy